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ABSTRACT 
The innate immune system represents the first line of host defence that reacts 
promptly to microbial attacks. This system relies on several families of 
pathogen-recognition receptors (PRRs), which recognize pathogen-associated 
molecular patterns (PAMP) on a broad range of pathogens. Toll-like 
receptors (TLRs), the best-characterised PRRs, act through the signal 
transduction pathways to induce production of the pro-inflammatory 
cytokines that participate in innate responses against pathogens and also 
provide signals for the activation of adaptive immunity.  
At birth, the immune system is characterised by immaturity and undeveloped 
functions. This is reflected in the greater susceptibilities of neonates to 
various pathogens, in particular viruses, such as herpes simplex virus (HSV), 
respiratory syncytial virus, and cytomegalovirus. The aim of this thesis was 
to characterize in umbilical cord blood cells the expression profiles of PRRs 
that sense viral nucleic acids, and to ascertain whether these profiles 
represent a molecular basis for the inadequate neonatal responses to viral 
infections. Neonatal natural killer (NK) cells, normally involved in anti-viral 
and anti-tumour defences, were found to lack TLR3 mRNA and protein 
expression. Consequently, they could not respond to the TLR3 ligand 
poly(I:C) by producing IFN-γ, which, in contrast, was abundantly secreted by 
adult NK cells. The neonatal NK cell cytotoxicity against tumor cells, HSV-
infected targets, and in stimulation with HSV was also impaired. In similarity 
to the cord blood NK cells, TLR3 mRNA expression was low in decidual NK 
cells obtained from placentas at full-term delivery, but not in mononuclear 
 blood cells from pregnant women. In adult mononuclear blood cell 
populations, the highest level of TLR3 expression was associated with the 
cytotoxic CD56
dim
 NK cell subset.  
Dendritic cells (DCs) link the innate and adaptive immunity systems through 
TLR signalling. DCs also induce tolerance to host antigens, and regulate the 
magnitude of immune responses by suppressing immune reactions, partly 
mediated by the tryptophan-degrading enzyme indoleamine-2,3 dioxygenase 
(IDO). Cholera toxin (CT), which is a strong bacterial immunogen and a DC-
maturation-promoting adjuvant, was investigated in the context of IDO 
induction. CT-pulsing of DCs induced the expression of IDO mRNA but not 
the production of IDO protein. However, CT primed for CD40L-induced 
IDO mRNA and protein activity. The CT-pulsed DCs potently stimulated 
allogeneic and autologous T-cell responses, and these activities were not 
regulated by IDO. However, CD40L-induced IL-12p40 production was 
dependent upon IDO. 
The mechanism of CT adjuvanticity has been addressed with respect to 
interference with viral-recognition receptor pathways. Among the different 
viral nucleic acid-sensing receptors, CT showed selective inhibition of TLR7 
mRNA expression. Although they represent the main mechanisms through 
which CT exerts its effects, the induction of cyclic adenosine monophosphate 
and PKA activation were not linked to the CT-mediated down-regulation of 
TLR7 mRNA. Instead, the PKC signalling pathway was implicated, as was 
IL-6.  
Overall, the results presented in this thesis reveal new thinking about the 
ways in which TLRs sense infections and how CT acts as an adjuvant, with 
implications for innovative vaccine development and elucidation of the 
immune pathways that protect us against infections. 
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SAMMANFATTNING PÅ SVENSKA 
Vi lever i en värld full av mikroorganismer. För att kunna överleva har alla 
högre organismer därför, under evolutionen, utvecklat olika former av 
försvarsmekanismer som dels hindrar mikroorganismerna från att komma in i 
vår kropp och dels dödar de mikroorganismer som ändå lyckats komma in. 
Dessa försvarsmekanismer kallar vi för vårt immunsystem. Hos människan 
brukar vi traditionellt prata om en medfödd immunitet som reagerar snabbt 
och brett på alla former av mikroorganismer, och om förvärvad immunitet 
som är specifik bara för just den infektion som vi drabbats av, som tar lång 
tid att utveckla men som har en minnesfunktion och därmed kan reagera 
ytterst snabbt och effektivt vid ny smitta. 
De vita blodkroppar som utgör stommen i det medfödda immunsvaret har 
olika strategier för att omedelbart veta om en mikroorganism har kommit in i 
vår kropp. Framförallt uttrycker de speciella receptorer både på cellytan och 
inne i cellerna, som känner igen strukturer som är unika för mikroorganismer, 
dvs som inte finns på våra egna celler och organ. I min avhandling har jag 
studerat regleringen av två sådana receptorer. Jag har dels undersökt om 
nyfödda barn, som vi vet är ytterst infektionskänsliga, inte har like mycket 
receptorer i sina celler som vi vuxna, och dels om bakterieprodukter kan 
modifiera uttrycket av dessa receptorer. Jag har kunnat visa att barn saknar en 
speciell receptor som heter TLR3. Denna receptor är viktig för att vi ska 
skydda oss mot herpesvirus, och jag har i mina försök kunnat visa att celler 
från nyfödda barn saknar förmågan att avdöda herpesvirus-infekterade celler. 
Dessutom visar mina studier att ett bakterietoxin påverkar uttrycket av en 
annan receptor, TLR7. Celler som normalt har höga halter av denna receptor 
slutade helt att syntetisera receptorn när de kom i kontakt med toxinet. Detta 
visar ett nytt sätt som bakterier manipulerar vårt immunförsvar på. 
Vårt immunsvar ska reagera på allt som är farligt och icke kroppseget, men 
ska inte reagera mot vår egen kropp och inte heller mot det vi andas in eller 
äter. Om immunsystemet gör det så utvecklas vi autoimmuna sjukdomar och 
allergier. Immunsystemet har därför en mängd olika kontrollsteg som ska 
styra när och hur det ska reagera. Jag har studerat ett enzym som påverkar 
vårt specifika immunsystem, och stänger av det. Enzymet brukar kallas för 
IDO. Vi vet sedan tidigare att IDO behövs för att en gravid kvinna inte ska 
stöta bort sitt foster. Dessvärre kan IDO även vara ett hinder när vi vill att 
immunsystemet ska attackera en tumör. Forskargruppen jag arbetat 
tillsammans med under min doktorandtid har utvecklat en immunologisk 
terapi som, i alla fall hos möss som har en tumör, leder till att tumören 
 försvinner. Terapin bestod av celler, tumörantigen och bakterietoxin. För att 
säkerställa att behandlingen inte gav upphov till IDO-aktivering har jag 
undersökt hur bakterietoxinet påverkar IDO-syntesen och den biologiska 
aktiviteten hos IDO. Mina resultat visar att bakterietoxinet inte bidrog till mer 
IDO aktivitet vilket var bra. 
Sammanfattningsvis har jag studerat hur olika receptorer och molekyler som 
finns inne i våra vita blodkroppar påverkas dels av vår ålder och dels av vår 
omgivning. Min forskning har därmed bidragit med några små pusselbitar till 
den komplicerade värld som vårt immunsystem utgör.  
i 
LIST OF PAPERS  
This thesis is based on the following studies, referred to in the text by their 
Roman numerals. 
I Slavica L, Nurkkala-Karlsson M, Karlson T, Ingelsten M, 
Nyström J, Eriksson K. IDO expression and functional 
activity in dendritic cells exposed to cholera toxin.  
Scandinavian Journal of Immunology 2012; 76(2): 113-22. 
II Slavica L, Nordström I, Nurkkala Karlsson M, Valadi H, 
Kacerovsky M, Jacobsson B, Eriksson K. TLR3 impairment 
in human newborns. 
Journal of Leukocyte Biology 2013; 94(5): 1003-11. 
III Zenić L, Nordström I, Karlsson A, Eriksson K. Cholera 
toxin selectively blocks TLR7 expression in human 
lymphocytes.  
In manuscript  
ii 
CONTENT 
ABBREVIATIONS ......................................................................................... IV 
1 INTRODUCTION ....................................................................................... 1 
1.1 The immune system – an overview..................................................... 1 
1.2 Immune cells relevant for this thesis ................................................... 2 
1.2.1 Dendritic cells and the control of immune responses ................... 3 
1.2.2 DC subsets ................................................................................. 3 
1.2.3 T lymphocytes ............................................................................ 4 
1.2.4 DC maturation and T-cell activation ........................................... 4 
1.2.5 DC-primed Th cell polarisation ................................................... 6 
1.2.6 B lymphocytes ............................................................................ 7 
1.2.7 Natural killer (NK) cells and their roles in viral infections........... 7 
1.3 Receptors in the innate immune system .............................................. 9 
1.3.1 Toll-like receptors (TLRs) .......................................................... 9 
1.3.2 Why do TLRs not react to self-compounds? .............................. 11 
1.3.3 RIG-I-like receptors and other PRRs ......................................... 12 
1.3.4 Why have several danger-signalling systems? ........................... 12 
1.4 Immunosuppression ......................................................................... 13 
1.4.1 DC-induced T-cell tolerance ..................................................... 13 
1.4.2 Indoleamine 2,3-dioxygenase (IDO) ......................................... 14 
1.4.3 Innate immune system in newborns .......................................... 16 
1.5 Cholera toxin (CT) ........................................................................... 17 
2 AIM ...................................................................................................... 19 
2.1 Paper I - Immune regulation by IDO in CT-exposed DCs ................. 19 
2.2 Paper II - TLR3 in neonatal NK cells ............................................... 20 
2.3 Paper III - TLR7 in CT-exposed PBMCs .......................................... 22 
3 DISCUSSION .......................................................................................... 23 
3.1 Paper I ............................................................................................. 23 
3.2 Paper II ............................................................................................ 29 
iii 
3.3 Paper III........................................................................................... 33 
ACKNOWLEDGEMENT ................................................................................ 39 
REFERENCES .............................................................................................. 41 
APPENDIX ............................................. ERROR! BOOKMARK NOT DEFINED. 
 
  
iv 
ABBREVIATIONS 
  
ADP 
ALRs 
APCs 
BDCA 
cAMP 
CBMCs 
CD 
CpG ODN 
CT 
CTA 
CTB 
CTLs 
CTLA-4 
adenosine diphosphate 
AIM-2-like receptors 
antigen-presenting cells  
blood dendritic cell antigen 
cyclic adenosine monophosphate 
cord blood mononuclear cells 
cluster of differentiation 
CpG oligonucleotide 
cholera toxin 
cholera toxin A subunit 
cholera toxin B subunit 
cytotoxic T lymphocytes 
cytotoxic T lymphocyte antigen 4 
DAMPs damage-associated molecular patterns 
DCs 
GM-CSF 
HLA 
HPV 
HSV 
IDO 
IFI-16 
IFN 
IL 
IRF 
LPS 
MDA-5 
MDDCs 
MHC 
1-MT 
MyD88 
NF-κB 
dendritic cells 
granulocyte/macrophage-colony stimulating factor 
human leukocyte antigen 
human papillomavirus 
herpes simplex virus 
indoleamine 2,3-dioxygenase 
interferon gamma-inducible protein 16 
interferon 
interleukin 
interferon regulatory factor 
lipopolysaccharide 
melanoma differentiation-associated gene 5 
monocyte-derived dendritic cells 
major histocompatibility complex 
1-methyltryptophan 
myeloid differentiation factor 88 
nuclear factor κB 
NK cells 
NO 
PAMPs 
PBMCs 
pDCs 
PGE2 
PKA 
natural killer cells 
nitric oxide 
pathogen-associated molecular patterns 
peripheral blood mononuclear cells 
plasmacytoid dendritic cells 
prostaglandin E2 
protein kinase A 
v 
PKR 
poly(I:C) 
PRRs 
RIG 
RLRs 
SLE 
TCR 
TGF 
Th 
TRAF 
TRIF 
TLRs 
TNF 
protein kinase R 
polyinosinic-polycytidilic acid 
pattern-recognition receptors 
retinoic acid-inducible gene I 
RIG-I-like receptors 
systemic lupus erythematosus 
T-cell receptor 
transforming growth factor 
T helper 
TNF receptor-associated factor 
TIR-domain-containing adapter-inducing interferon β 
Toll-like receptors 
tumor necrosis factor 
  
 
  
vi 
 
Lucija Zenić 
1 
1 INTRODUCTION 
”Yet it was with those who had recovered from the disease that the sick and 
the dying found most compassion. These knew what it was from experience, 
and had now no fear for themselves; for the same man was never attacked 
twice - never at least fatally.” [1] Without knowing the cause and the nature 
of the disease, the Greek historian Thucydides described the plague of Athens 
in 430 B.C. and noticed that those who had survived contagion were exempt 
from further episodes of the disease. The “exempted” ones are what we today 
call “immune”. The term originates from the Latin immunitas (“protected 
from”), which in ancient Rome denoted the exemption from civic duties 
afforded to senators, as well as individuals who were excused from the 
military or other service. Although the Roman poet Marcus Annaeus Lucanus 
(39–65 A.D.) was the first to use the word “immunes” in his epic poem 
“Pharsalia” to describe the resistance to snakebite of the Psylli tribe of North 
Africa [2], it was not until the late 19
th
 century (almost 2000 years later!) and 
the discoveries of the great immunologists Pasteur, Koch, Metchnikoff and 
others, that “immunity” became a commonly used expression in biology to 
define protection against certain diseases, especially infectious diseases. 
1.1 The immune system – an overview 
Central to the defence of an organism against disease is the immune system, 
which is defined as a complex system of cells, tissues, and organs that work 
together to combat attacks by different microorganisms and subsequent 
disease development. The foundation of the immune defence is the ability to 
discriminate normal from foreign entities, such as the disease-causing 
microbes (pathogens), as well as the detection of intrinsic tissues that have 
become transformed. This capability to discern “self” from “non-self” can be 
traced to a very early stage in evolution: genetically related sponges tend to 
fuse into large colonies, while unrelated sponges destroy the cells in the 
contact zone, thereby demonstrating a primitive form of tissue rejection.  
In vertebrates, the immune system is comprised of two functional entities; the 
innate and adaptive. The innate immune system represents the first line of 
immune defence and is active in a normal individual from birth. Its 
components are present in the blood, the skin, and the mucous membranes 
that line the gastrointestinal and respiratory tracts, which constitute both 
physical and chemical barriers to the invading pathogens. It involves 
leukocytes, such as neutrophils, monocytes/macrophages, natural killer cells,  
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and dendritic cells, and their secreted products (cytokines, chemokines, and 
complement proteins). The main feature of the innate immunity is a rapid but 
“non-specific” response that provides a basic level of resistance to an 
infectious disease.   
In contrast, the adaptive immune system becomes active only after an 
encounter with foreign substances, i.e., antigens, and is thus being acquired 
throughout life. It consists of T and B lymphocytes and their products, i.e., 
cytokines and antibodies, which circulate in the blood, lymphoid system, and 
tissues. These cells have a high specificity for a given antigen, ensuring the 
clearance of an infection, but also retrieving immunological memory, which 
enables the body to mount a quicker and stronger immune response upon a 
subsequent microbial/antigen encounter. 
 
1.2 Immune cells relevant for this thesis 
 
 
Figure 1. Components of the immune system with relevance to this thesis. 
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1.2.1 Dendritic cells and the control of immune 
responses 
It is now 40 years since Ralph Steinman and Zanvil Cohn, in trying to 
understand how T cells are activated, discovered a new cell type that they 
called the ‘dendritic cell’ (DC) [3]. Despite initial scepticism on the part of 
scientific community, the role of DCs in coordinating the immune response 
to foreign antigens by activating adaptive immunity, as well as in inducing 
tolerance to self-antigens, is now firmly established, and has given rise to 
DC-based therapeutic interventions. 
1.2.2 DC subsets 
DCs make up a heterogeneous cell population that resides in almost all 
peripheral tissues. In humans, they are generally divided into two major 
subsets based on origin: myeloid DCs and lymphoid (plasmacytoid) DCs 
(Table 1). Myeloid DCs are usually referred to as “classical” or conventional 
DCs. Differentiation of DCs along the myeloid lineage gives rise to several 
different subsets of myeloid DCs with specific localisations: i) Langerhans 
cells in the skin epidermis; ii) interstitial DCs in the dermis and most other 
organs, mainly in connective tissues; and iii) blood myeloid DCs, which can 
be further divided into BDCA-1
+
 and BDCA-3
+
 cells [4]. Plasmacytoid DCs 
(pDCs) are of lymphoid origin, and are found in the blood and in the T-cell 
zones of lymphoid organs.  
 
Table 1. The main human DC subsets, their origins, and tissue distributions 
 
 
 
 
The type and function of a DC are dynamically influenced by external 
stimuli. Monocytes that infiltrate an inflammatory site can differentiate into 
macrophages or monocyte-derived DCs (MDDCs) [5]. However, these 
MDDCs are different than the DCs that exist under homeostatic conditions 
[6], and their existence and the rate of monocyte-to-DC conversion in vivo 
remain subjects of debate [7]. Nonetheless, MDDCs are easily generated in 
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vitro by culturing monocytes with granulocyte-macrophage colony-
stimulating factor (GM-CSF) and IL-4 and are widely used for in vitro 
studies of human DC function. This is something that we have taken 
advantage of in our studies.  
In mice, DCs are categorised into myeloid DCs and pDCs, while the resident 
DCs in lymphoid tissues are subdivided into CD8α- DCs (myeloid-origin), 
and CD8α+ DCs (lymphoid-origin); the human counterpart of the letter has 
only recently been assigned as blood BDCA-3
+
 DCs [8]. Besides the 
existence of many DC subsets in both species, their levels of homology are 
still not completely understood and their functional equivalences remain to be 
determined. 
1.2.3 T lymphocytes 
Highly specialised T cells comprise a pool of numerous clones, each with 
surface T-cell receptors (TCRs) that are specific for a single antigen. There 
are two well-defined subpopulations of T cells: 
Cytotoxic T lymphocytes (CTL), generally defined as CD8
+
 T cells, destroy 
cells infected with intracellular pathogens (viruses or bacteria), tumour cells, 
and the cells of a grafted foreign tissue. The mechanism underlying this T 
cell-mediated cytotoxicity involves the release of cytoplasmic granules that 
contain perforin proteins, which create perforations in cells, and granzymes, 
which induce programmed cell death (apoptosis) in target cells.  
T-helper (Th) lymphocytes (CD4
+
 T cells) coordinate immune responses by 
releasing cytokines.  Depending on the type of cytokine that it secretes, the 
Th cell can contribute to the activation of cytotoxic T cells, B cells, 
macrophages, and many other cell types. 
 
1.2.4 DC maturation and T-cell activation 
In peripheral tissues, immature DCs constantly sample antigens from the 
microenvironment. The antigens that are internalised (by phagocytosis, 
endocytosis or micropinocytosis) are processed into peptides and loaded onto 
major histocompatibility complex (MHC) class I (MHC I) and class II (MHC 
II) molecules for antigen presentation. Microbial components as well as the 
inflammatory cytokines released by other cell types in response to microbes, 
represent a “danger” signal that induces DC maturation [9, 10]. This process 
is characterised by the up-regulation of MHC and co-stimulatory molecules, 
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cytokine production, and altered expression of chemokine receptors. 
Eventually, the DCs migrate to the secondary lymphoid organs (spleen, 
lymph nodes, lymphoid tissues lining the mucosal surfaces), where they 
present antigens to naive CD4
+
 and CD8
+
 T cells, which recognise a specific 
antigen-MHC complex, thereby providing a “Signal 1” for T-cell activation 
(Figure 2). The TCRs of the CD8
+
 T cells, together with the CD8 co-receptor, 
recognise antigens on the MHC I molecules that present peptides of 
intracellular proteins (intrinsic proteins or those from intracellularly 
replicating pathogens). The TCRs of CD4
+
 T cells, in combination with the 
CD4 co-receptor, recognise the peptide of extracellular antigens on MHC II 
molecules. DCs interact via the co-stimulatory molecules CD80 and CD86 
with CD28 molecules on T cells, generating the signal referred to as a 
“Signal 2”. A final DC maturation step is achieved when the up-regulated co-
stimulatory CD40 molecules bind to their CD40 ligands (CD40L) on CD4
+
 T 
cells, resulting in: a) further up-regulation of co-stimulatory molecule 
expression and augmentation of the T-cell-stimulatory capacity; b) T cell-
derived IL-2 production, which drives T-cell proliferation; and c) DC-derived 
IL-12 production, which governs a Th1-type CD4
+
 polarisation and CTL 
differentiation; the letter supplies a polarising “Signal 3”. Thus, during 
pathogen invasion, the DCs ensure that harmful antigens collected at the 
periphery, together with the co-stimulatory signals and the secreted 
cytokines, alert the antigen-specific T cells and harness the powerful adaptive 
system.  
 
Figure 2. The main receptors involved in DC-T cell interactions. 
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1.2.5 DC-primed Th cell polarisation 
In addition to their effects on DC maturation, the danger signals (i.e., 
pathogen components, pathogen-sensing receptors, and pro-inflammatory 
cytokines), influence DC-mediated polarisation of naive Th cells. Upon 
sensing a pathogen, the DCs (and other cell types) secrete cytokines that are 
instrumental in initiating an immune response. Depending on cytokine that is 
present in proximity to the naive Th cell (i.e., a Th0 cell) when it recognises 
an antigen presented by a DC, the Th0 cell will mature and differentiate into 
one of the following types of Th cell (Figure 3): 
- Th1 cells, which secrete “Th1 cytokines”, in particular IFN-γ. 
They trigger cell-mediated immunity (e.g., cytotoxic T cells), 
crucial for combating intracellular pathogens and tumours, and 
play roles in both inflammation and autoimmunity; 
- Th2 cells, which secrete “Th2 cytokines”, such as IL-4, IL-5, and 
IL-13, and activate macrophages and B cells, which function in 
defences against extracellular pathogens;   
- Regulatory T cells (Tregs; defined as CD4+CD25+Foxp3+), 
which regulate the magnitude of an immune response by 
inhibiting the proliferation of innate and adaptive immune cells, 
so as to counterbalance excessive reactions. As part of normal 
homeostasis, Tregs participate in immune tolerance (non-
reactivity) to self-antigens; 
- Th17 cells, which secrete IL-17, IL-21, and IL-22 and activate 
neutrophils, are involved in eradicating extracellular microbes. 
Th17 cells are also implicated in several autoimmune disorders.  
CD40L [11], IFN-γ [12], and lipopolysaccharide (LPS) [12] stimulate potent 
IL-12 production and Th1 induction by DCs. In contrast, anti-inflammatory 
molecules, such as IL-10, transforming growth factor β (TGF-β), 
prostaglandin E2 (PGE2) [12], and the DC co-stimulatory molecule OX40L 
[13], are stimulators of Th2 development. Other factors, such as the duration 
of DC maturation, also contribute to the Th1/Th2 balance; at early stages of 
activation, DCs secrete higher levels of IL-12 [14], whereas during prolonged 
activation, DCs cease IL-12 production and preferentially induce Th2 
responses [15]. 
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Figure 3. Dendritic cell-mediated polarisation of naive Th cells. 
 
1.2.6 B lymphocytes 
B cells are specialised in antibody production in response to infection or 
vaccination. In addition, they act as antigen-presenting cells (APC), 
particularly during recall responses, and as cytokine-secreting regulatory cells 
to suppress inflammatory responses [16]. The immune responses mediated by 
B cells are part of humoral immunity (from the Latin, humor = body liquid, 
where the components are found) and are mainly aimed at combating 
extracellular pathogens, although antibodies also inhibit intracellular 
pathogen entry into cells and neutralise bacterial toxins. 
 
1.2.7 Natural killer (NK) cells and their roles in 
viral infections 
NK cells play important roles in innate immunity to viruses and tumours. 
Based on the density of the CD56 marker on the cell surface, NK cells are 
categorised into two subsets: 1) the CD56
bright
CD16
dim/-
 subset, which 
accounts for 10% of the NK cells in the blood and upon activation mainly 
produces high levels of cytokines, primarily IFN-γ [17, 18]; and 2) the 
CD56
dim
CD16
+
 subset, which accounts for more than 90% of circulating NK 
cells and mainly  mediates natural cytotoxicity (without the need for prior  
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sensitisation with an antigen) and antibody-dependent cytotoxicity [19, 20]. 
The activation of NK cells is primarily determined by the predominant 
signals received from the activating receptors and inhibitory receptors. These 
receptors recognise host proteins that are produced during the stress of 
malignant transformation, as well as the MHC I or MHC I-like molecules 
that are normally present on all nucleated cells. The recognition of stress 
ligands by activating receptors, in combination with the absence of MHC I 
ligands for inhibitory receptors, trigger NK cell-mediated responses. This 
represents an “alternative” recognition strategy that is based on the absence 
of typical self-MHC I molecules on the surface of the target cell - the 
“missing self” hypothesis proposed in 1986 by the Swedish immunologist 
Klas Kärre [21].  
Initially discovered based on their ability to kill rapidly tumour cells in the 
absence of antigen-specific recognition [22], NK cells were subsequently 
identified as innate lymphocytes that are involved in controlling certain viral 
infections. A large body of evidence supports the role of human NK cells in 
antiviral defence. This is exemplified by immunocompromised individuals 
who have a primary immunodeficiency of NK cells and who suffer from 
severe, recurrent, and often life-threatening viral infections [23]. Patients 
with impaired NK cell function experience severe herpesvirus infections, and 
when there is a complete absence of NK cells, disseminated herpes simplex 
virus (HSV) disease [24]. The association between NK cell deficiency and 
susceptibility to HSV underlines the importance of NK cells in defence 
against HSV infection. In vitro studies have confirmed that NK cells play a 
crucial role in inhibiting HSV replication [25]. This knowledge has been 
validated in several murine models of viral infection. Murine and human NK 
cells have similarities in terms of function, activation, and signalling 
pathways. However, the murine NK cell receptors are structurally unrelated 
to their human counterparts (e.g., inhibitory receptor Ly49 versus KIR), and 
since there is no murine homologue of CD56, the existence of two analogous 
subsets in mice remains unresolved. Murine NK cells can be distinguished 
based on their expression of CD27
low
 and CD27
high
 [26], and these subsets 
show both similarities and dissimilarities to human CD56 subsets [27]. 
Therefore, results obtained using murine NK cells should be extrapolated 
with caution to the human situation. In this thesis, the focus is on human NK 
cells. 
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1.3 Receptors in the innate immune system  
The innate immune system combats a broad spectrum of intruders with such 
efficiency that activation of adaptive immunity is not always necessary. 
Innate immune responses to pathogens are based on the recognition of 
specific molecular structures of the invading micro-organism, so-called 
pathogen-associated molecular patterns (PAMPs), by specific receptors on 
the innate immune cells, which are termed ’pattern-recognition receptors’ 
(PRRs). These PRRs are distributed on the surface of and inside the host cell 
and recognise a large variety of PAMPs. Apart from the different microbes, 
PRRs recognise transformed host molecules and complexes as “danger” 
signals, which are produced during cellular stress, infection or inflammation 
[28]. Host molecules that are released from damaged cells and found in 
“ectopic” (not natural) locations can be recognised as ’damage-associated 
molecular patterns’ (DAMPs) and they also act as endogenous PRR ligands. 
Some PRRs are phagocyte receptors that trigger the ingestion of the 
recognised pathogen, while others are chemotaxis receptors that govern the 
migration of macrophages and neutrophils from the blood to the site of 
infection. The third group of PRRs includes signalling PRRs, which are 
specialised in boosting both the innate responses and subsequent adaptive 
responses.  
1.3.1 Toll-like receptors (TLRs) 
The significance of Toll-like receptors is best illustrated by the fact that 
Bruce Beutler and Jules Hoffmann were awarded the 2011 Nobel Prize in 
Medicine or Physiology for their discovery of these receptors. Charles 
Janeway postulated the existence of such PRRs in mammals already in 1989 
[29], and more than two decades of research conducted by his group and 
other groups since then have led to the identification of TLRs and their 
respective ligands, as well as the elucidation of their roles in linking innate 
and adaptive immunity [30-32]. TLRs represent an evolutionary conserved 
family of signalling receptors (being present in plants, insects, and 
vertebrates) that sense a large repertoire of PAMPs. To date, ten TLRs have 
been identified in humans, each specialised for different structures (Figure 4). 
TLR1, TLR2, TLR4, and TLR6 are expressed on the cell surface and 
recognise lipid complexes, while TLR5 detects the flagellin protein of the 
flagellum organelle. TLR3, TLR7, TLR8, and TLR9 detect viral and bacterial 
nucleic acids and are located on intracellular vesicles, mainly endosomes. 
While the ligand for TLR10 is unknown, there is homology between this 
receptor and TLR1. The different cellular locations of the TLRs reflect their 
roles as sentinels for pathogens that enter the cell via various routes.  
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Figure 4. Recognition of PAMPs by their respective TLRs (adapted from: Christmas, 
P. (2010) Toll-like receptors: Sensors that detect infection. Nature Education 
3(9):85) 
 
After ligand binding, TLR dimerization occurs (thereby forming 
homodimers or heterodimers, such as TLR1/TLR2, TLR2/TLR6, and 
TLR7/TLR8), and this initiates a signalling cascade that involves various 
cytoplasmic adaptor molecules, kinases, and transcription factors. For the 
TLRs, signalling engages the MyD88 adaptor molecule, with the exceptions 
of TLR3, which uses TRIF, and nuclear factor-κB (NF-κB), which initiates 
transcription of the genes for pro-inflammatory cytokines and chemokines 
(e.g., IL-1, IL-6, IL-8, IL-12, TNF-α), leading to inflammatory responses. 
Signalling from the endosomal TLRs can also recruit the interferon-
regulatory factors (IRF-3 and, IRF-7), resulting in the secretion of type I 
interleukins (IFN I; IFN-α and IFN-β), which are the main cytokines 
implicated in anti-viral responses (Figure 5). Other consequences of TLR 
signalling are the induction of adhesion molecules that enable leukocyte 
migration to the site of infection, DC maturation, and ultimately, T-cell 
activation. 
While TLRs are present in most tissues, their expression levels are higher in 
tissues that are exposed to the external environment (e.g., lung and 
gastrointestinal tract) and lymphoid organs, such as the spleen [33]. TLRs are 
prominently expressed on antigen-presenting cells, such as DCs, 
macrophages, and B cells. Although immune cells can express the mRNA 
species for all TLRs, leukocytes have a cell type-specific pattern of TLR 
expression, which tailors their activities against microbes. 
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Figure 5. Schematic of the TLRs and other PRR signalling molecules in cells. 
 
 
1.3.2 Why do TLRs not react to self-compounds? 
Surface-localised TLRs mainly recognise PAMPs that are typical of 
microbes, as these structures, such as the LPS of Gram-negative bacteria or 
the lipoteichoic acid of Gram-positive bacteria, are not found in the host. 
Endosomal TLRs bind nucleic acids, some of which are also typical of 
pathogens (e.g., double-stranded RNA [dsRNA] or unmethylated CpG 
oligodeoxynucleotide [CpG ODN] motifs in DNA). However, studies have 
revealed that appropriate compartmentalisation of the ligands rather than a 
species-specific structure forms the basis for self-versus non-self 
discrimination; thus, both host and foreign nucleic acids can activate cells via 
TLRs, provided that the nucleic acid is located in the endosomes [34, 35]. 
Nonetheless, some intrinsic structures are recognised as endogenous TLR 
ligands, act as DAMPs, and provoke an inflammatory response [36]. For 
example, host nucleic acids can under certain circumstances bind to TLR7, 
TLR8, and TLR9 and induce inflammation [37]. For these reasons, TLR 
inhibition has been adopted as a strategy to reduce excessive inflammation, 
and molecular modulators that target TLR signalling have been developed to 
control the progression of inflammatory and autoimmune diseases. 
 
Developmental and cholera toxin-induced alterations in the expression of intracellular 
signalling molecules 
12 
1.3.3 RIG-I-like receptors and other PRRs 
Recently, a cytosolic network of signalling receptors that detects PAMPs 
located in the cytosol was discovered (Figure 5).  
Retinoic acid-inducible gene I (RIG-I-like receptors (RLRs) are RNA 
helicases that sense the viral genomic dsRNA, viral replication intermediates, 
and viral transcription products, and can thus recognise recognises a variety 
of viruses [38]. The family comprises RIG-I and melanoma differentiation-
associated gene 5 (MDA-5) receptors, which control viral infections. In 
addition, IFN-inducible, dsRNA-dependent protein kinase R (PKR) is a 
cytoplasmic serine-threonine kinase that also binds dsRNA and mediates the 
inhibition of viral replication and the apoptosis of virus-infected cells [39].  
AIM2-like receptors (ALRs) are part of a recently discovered family of 
cytoplasmic DNA sensors. The representative interferon gamma-inducible 
protein 16 (IFI-16) is a dsDNA receptor that acts in response to DNA viruses 
[40] and also apparently to bacterial DNA during bacterial infection [41].  
These receptors, which are found in most tissues and cell types, signal via 
NF-κB, IRF-3 or IRF-7 to activate the expression of the gene for IFN-I, as 
well as other genes involved in host defence. 
1.3.4 Why have several danger-signalling systems? 
Considering the various ligand specificities of TLRs, RLRs, and ALRs, it is 
clear that an individual PAMP can be detected by more than one PRR. As 
example, viral or synthetic dsRNA is recognised by both TLR3 and MDA-
5/RIG-I, exogenous DNA is recognised by TLR9 and IFI-16, and flagellin is 
bound by TLR5 and a NOD-like receptor (NLR) family member. Given this 
overlap of binding agonists, it might seem at first glance that there is a degree 
of redundancy in PAMP recognition. One possible explanation for this is that 
TLRs are more suited to sensing pathogens that are present extracellularly. 
However, once inside the cell, RLRs and NLRs are adept at detecting 
actively replicating pathogens. An alternative explanation is that RLRs act as 
initial viral sensors and triggers of IFN, which enhances TLR function and 
promotes development of the TLR-mediated adaptive response [42, 43]. 
Furthermore, since many viruses target these signalling pathways as a part of 
their immune evasion strategies [44], the inhibition of one system can be 
compensated for by the activity of another system. Therefore, TLRs and other 
PRRs seem to engage in crosstalk to control viral replication [43]. The beauty 
of this system is that a microbe can be detected by the immune system 
irrespective of its location. 
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In this thesis, I have studied TLR3 and TLR7 in particular. Polyinosinic-
polycytidilic acid [poly(I:C)], which is a synthetic analogue of dsRNA, 
serves as a prototypic TLR3 ligand for studying the interactions of TLR3 
with dsRNA. dsRNA is produced during the replication of most viruses, and 
its presence stimulates TLR3-mediated responses. Studies performed in mice 
have shown that the administration of poly(I:C) in an influenza vaccine 
induces a strong anti-viral effect that is not seen in the absence of the 
synthetic ligand [45]. Poly(I:C) also improves peptide-based cancer vaccines 
by eliciting tumour-specific CTLs. In contrast to its successful use in mice, 
poly(I:C) use in humans has proven to be problematic  due to its degradation 
by serum nucleases [46] and safety issues associated with the administration 
of higher doses. Safer derivatives of poly(I:C) have been used in preclinical 
studies to generate mature MDDCs with strong IL-12 production and Th1-
polarisation potential [47]. Importantly, poly(I:C) is also a ligand for RIG-I 
and MDA-5, and is thus not involved solely in TLR3 signalling. 
 
 
1.4 Immunosuppression 
1.4.1 DC-induced T-cell tolerance 
Induction of immunity is not the only effector function of DCs. Equally 
important is the induction of tolerance, which is defined as host 
unresponsiveness to antigens. This lack of responsiveness prevents 
undesirable immune responses to harmless substances and to self-antigens, 
which would otherwise lead to autoreactive lymphocyte activation and 
detrimental attacks on tissues of the body (autoimmunity). In the thymus, 
DCs are involved in the elimination of self-reactive immature T cells, and 
thus establish so-called “central tolerance”. In the peripheral tissues, the 
steady-state DCs are also likely to be tolerogenic; endocytosis of antigens by 
itself does not induce DC activation, and MHC-linked antigen presentation 
alone does not stimulate naive T cells in the absence of pathogen- or 
inflammatory signal-initiated DC maturation [48]. Instead, these immature 
DCs do not provide T-cell co-stimulation but cause activation-induced T-cell 
death, or anergy (inertness) [49]. Thus, in the absence of Signals 2 and 3, 
DCs provoke T-cell tolerance rather than T-cell activation, and this 
“peripheral tolerance” that is mediated by low-level migratory DCs 
contributes to immune homeostasis.   
Developmental and cholera toxin-induced alterations in the expression of intracellular 
signalling molecules 
14 
 
1.4.2 Indoleamine 2,3-dioxygenase (IDO) 
DCs employ a range of mechanisms to establish tolerance. Indoleamine 2,3-
dioxygenase (IDO) is a tryptophan-metabolising enzyme that can inhibit T-
cell proliferation and suppress immune responses. The history of how IDO 
was discovered is intriguing. Isolated in 1963 from rabbit intestine as an 
enzyme implicated in the kynurenine pathway [50] (Figure 6), IDO had been 
known for decades for its ability to deplete the environment of the essential 
amino acid tryptophan, thereby inhibiting the growth of bacteria, viruses, and 
parasites. In 1998, IDO was re-discovered in a rather peculiar way through 
the seminal work of Munn and colleagues, who found that IDO inhibited 
maternal T-cell activation and prevented the rejection of allogeneic foetuses 
in mice [51]. This has placed IDO in a completely different biological context 
and opened up a new avenue of research into the immunoregulatory 
properties of this metabolic enzyme.  
 
Figure 6. Schematic of the kynurenine pathway. 
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There are several possible mechanisms through which IDO blocks T-cell 
activation. First, the absence of tryptophan during T-cell activation leads to 
cell cycle arrest and subsequent inhibition of T-cell proliferation [52], or it 
induces apoptosis [53]. Second, tryptophan metabolites per se are toxic for T 
cells, thereby preventing their expansion [54, 55]. Interestingly, these 
metabolites induce selective apoptosis of Th1 cells over Th2 cells [56]. Third, 
IDO can activate regulatory T cells, which suppress even further the effector 
T-cell responses [57].  
IDO is expressed in tissues with immune privilege, such as the placenta, gut, 
and the central nervous system. It is induced in APCs during inflammation 
through exposure to pro-inflammatory cytokines, especially IFN-γ. The T 
cells themselves participate in IDO stimulation, in that ligation of the CTLA-
4 molecules on activated CD4
+
 T cells to the CD80/CD86 co-stimulatory 
molecules on DCs represents a strong signal for IDO induction and 
suppression of T-cell mediated immunity [58].  
Under normal physiological conditions, the activity of IDO favours the 
maintenance of homeostasis and the prevention of autoimmune disorders. 
However, IDO is abundantly expressed in the tumours and tumour-draining 
lymph nodes of mice, and since it prevents attacks by tumour-specific CTLs, 
this represents a tumour evasion mechanism [59]. In humans, IDO expression 
and the consequent IDO-mediated activation of Tregs may be the basis for 
therapeutic DC vaccination failure [60]. 
Interestingly, while IDO shows adverse effects on T cells, as well as on B 
cells and NK cells [55], it does not exert these activities on DCs. IDO can 
have a stimulating role in DC activation, manifested as the up-regulation of 
co-stimulatory and chemotactic molecules and, in apparent contradiction to 
what was previously postulated [61], increased T-cell-stimulatory capacity 
[62]. The mechanisms that determine whether IDO has a negative or positive 
outcome on the T-cell-stimulatory capacity of DCs remain elusive, although 
complex spatiotemporal regulation is likely to be involved. 
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1.4.3 Innate immune system in newborns 
The immune system of newborns is very different from that of children or 
adults, in that it is characterised by functional immaturity and as a 
consequence, increased susceptibility to infections. This peculiarity stems 
from the challenges faced during life in utero, i.e., the avoidance of harmful 
pro-inflammatory responses and alloreactions between the mother and foetus, 
which could result in spontaneous abortion or pre-term delivery [63]. These 
conditions shape an immunological forma that circumvents the inflammatory 
Th1-type polarising reactions and that is skewed towards Th2-type responses. 
This is a double-edged sword in that it reduces the ability of the neonate to 
fight intracellular pathogens, the clearance of which demands a strong Th1 
cellular immune response. It is also the reason why neonates are poor 
responders to many vaccines (e.g., vaccines against polio, measles, and 
mumps) [64-66].  
The immaturity of the neonate immune system is usually ascribed to the 
sterile uterine environment and the consequent lack of antigen-experienced T 
and B lymphocytes, which account for the lack of pre-existing 
immunological memory [67]. However, inadequate T-cell activation is a 
consequence of the weak antigen-presenting properties of the APCs. In 
neonates, the DCs are immature and this immaturity is characterised by 
decreased expression of MHC and co-stimulatory molecules and reduced 
level of IL-12 secretion, which result in an inability to stimulate efficient Th1 
responses [68]. Apart from IL-12, neonatal DCs and monocytes produce 
lower levels of the pro-inflammatory cytokines TNF-α and IFN type I (IFN-
α, IFN-β) and higher levels of IL-6, IL-10, and IL-23, as compared with their 
adult counterparts [69], thus reflecting the above-mentioned Th2 bias (which 
is more suitable to defence against extracellular pathogens). The lack of IL-
12 affects the production of IFN-γ by neonatal NK cells [70], which also 
have decreased killing ability; their cytotoxicity for tumour cells is less than 
50% that of adult NK cells [71, 72]. The innate immune impairment in 
neonates also includes quantitative defects, such as altered levels of blood 
complement proteins, which can be 10%–70% lower than in adults [73, 74], 
and fewer neutrophil progenitor cells. The neutrophils of neonates show 
impairments in chemotaxis, phagocytosis, and microbicidal capacity [75, 76].  
Neonatal NK cells have several functional defects that may render newborns 
more prone to viral infections. In this respect, they are deficient in killing 
HSV-infected cells [77] and have a reduced level of HSV-specific IFN-α 
secretion [78]. The impaired function can be attributed to the intrinsic 
features of neonatal NK cells, as their content of cytoplasmic granules, which 
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mediate cytotoxicity, is decreased and the expression of inhibitory receptors 
is increased [71]. In addition, the malfunction may be exacerbated by the 
lower levels of secretion of the NK-stimulating cytokines IL-12 and IFN-α by 
other cord blood cells. Taken together, these phenotypic and functional NK 
cell defects correspond to the impaired ability of neonates to control HSV 
infections. 
Maturation of the immune system is age-dependent and is acquired during 
infancy when newborns, in an antigen-rich environment, encounter microbe-
derived TLR agonists. Although TLRs are at the basis of this process, their 
ontology is not well-characterised. TLR expression may be lower in 
newborns than in adults, e.g., in blood-derived DCs [79]. In contrast, TLR 
expression may be fully developed during gestation, e.g., umbilical cord 
blood monocytes from full-term newborns express as high levels of TLR4 as 
do adults, a phenomenon that is not seen in pre-term newborns [80]. 
However, even when neonatal cells express TLRs to the same degree as adult 
cells, they still have impaired responses to certain TLR ligands, such as 
diminished TNF-α production by neonatal monocytes after stimulation of 
TLR2, TLR4 or TLR7 [81]. The mechanistic explanation for this is 
incomplete but involves differences in the levels of cytokine transcripts and 
neonatal plasma factors [81, 82]. Therefore, impairments in the maturation of 
TLR expression and TLR responsiveness predispose newborns to certain 
infections during early life, such as infections with HSV, respiratory 
syncytial virus, and Mycobacterium tuberculosis [83].  
 
 
1.5 Cholera toxin (CT) 
Cholera toxin (CT), which is produced by Vibrio cholerae and is a causative 
agent of cholera in humans, is a potent immunogen and adjuvant [84]. CT is 
composed of a catalytic A subunit (CTA) and a pentameric cell-binding B 
subunit (CTB). The adenosine-diphosphate (ADP)-ribosylating activity of 
CTA leads to an increase in cAMP and chloride channel protein activation, 
leading to excessive loss of ions and water. In humans, even small amounts 
of CT provoke drastic diarrhoea and dehydration, so the adjuvant effect of 
CT cannot be observed in humans. In experimental animals, CT is far less 
toxic and can be used both in immunisation studies and as an adjuvant.  
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In mice, the adjuvant effects of CT are: 1) increased permeability of the 
intestinal epithelium, resulting in increased uptake of antigens; and 2) 
stimulation of mucosal IgA antibody production. The most important 
adjuvant effect of CT is thought to be on antigen presentation exerted by 
DCs, macrophages, and B cells. CT provokes the up-regulation of MHC and 
co-stimulatory molecules, as well as increased expression of the CCR7 and 
CXCR4 chemokine receptors on both murine and human DCs [85, 86]. An 
important adjuvant mechanism of CT is mediated through the secretion of IL-
1β, which induces DC maturation and acts as a mucosal adjuvant for co-
administered protein antigens [87]. In mice, the adjuvant effect of CT is 
exerted on splenic DCs [88].  
Although CT is probably one of the most intensively investigated microbial 
toxins and one of the most powerful adjuvants known, being widely used in 
experimental animals as a mucosal adjuvant or as a carrier molecule for 
covalently linked antigens [85, 89], the mechanism underlying its 
immunomodulatory effects is not completely known.  
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2 AIM 
The overall goal of this thesis was to study the cellular intracellular signalling 
events of the innate immune system. 
2.1 Paper I - Immune regulation by IDO in 
CT-exposed DCs  
We developed a combined DC vaccine that has proven successful in the 
eradication of experimental tumours in mice. It is based on the use of CT 
both as an adjuvant and an antigen carrier. The antigen conjugated to CT 
enhanced >1000-fold the antigen-presenting capacity of the DCs in vitro, 
amplified T-cell responses in vivo after DC vaccination, and induced tumour-
specific CTLs that eradicated an already established experimental tumour in 
mice [85, 90-92]. The conjugation of CT with the E7 protein of human 
papillomavirus (HPV) also gave rise to an efficient DC vaccine and induced 
the elimination of E7-expressing tumours in mice, provided that the 
vaccination was combined with the injection of the TLR9 agonist CpG ODN 
[93]. In addition, CT conjugation to HPV 16 E7 has been shown to enhance 
significantly E7-specific T-cell responses ex vivo in women with cervical 
dysplasia [94].   
In several studies published a decade ago, it was shown that IDO has strong 
T-cell-suppressive characteristics that have negative impacts on the immune 
system, e.g., in cancer cases. Therefore, we assumed that IDO would not be 
expressed in immunogenic DCs, which drive a powerful cell-mediated 
immunity against tumours (this was before the traditional view of IDO was 
modified based on the findings that IDO may contribute to DC activation and 
have a stimulatory effect on immune responses). We wanted to investigate 
whether the adjuvanticity of CT would bypass IDO in the activation of DCs 
and subsequent expansion of T cells (Figure 7). 
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Figure 7. Hypothetical basis for the study. 
 
The hypothesis underlying the work in Paper I was that:  
♪  CT activates DCs without inducing the immunosuppressive enzyme IDO 
 
2.2 Paper II - TLR3 in neonatal NK cells 
The defective responses of neonatal NK cells to HSV are linked to the 
increased susceptibility of newborns to HSV infections. Newborns are 
extremely sensitive to HSV, and infection with HSV-1 or HSV-2 can lead to 
disseminated disease with multiple organ failure, including brain 
inflammation (encephalitis). HSV-2 causes a more frequent and severe form 
of neonatal herpes infection [95, 96] and is the etiological agent in 80% of 
cases of neonatal encephalitis [97]. 
Several seminal studies conducted by the group of Jean-Laurent Casanova 
reveal that many children with severe HSV-1 encephalitis have a primary 
deficiency in TLR3 signalling. In particular, autosomal mutations in four 
proteins of the TLR3 signalling pathway have been identified, as follows: 
dominant-negative mutations of the TLR3 protein [98, 99] and TRAF3 
adaptor molecule [100]; a recessive mutation of UNC93B1, which is 
involved in endosomal TLR signalling [101, 102]; and both dominant and 
recessive mutations of the TRIF adaptor molecule [103]. As a consequence of 
these mutations, IFN I production was abolished. It was concluded that 
impairment of the TLR3 pathway predisposes for HSV-induced encephalitis. 
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This means that TLR3 signalling is crucial for controlling HSV replication, 
providing resistance to HSV in the central nervous system.  
We investigated whether a lack of TLR3 or of another viral-sensing receptor 
determined the poor responses of neonates to viruses and their higher 
susceptibility to viral infections. The expression and function of signalling 
PRRs in neonates have not been systematically scrutinised. TLR expression 
was analysed in neonatal monocytes and T lymphocytes, and they showed the 
same levels of expression of TLRs 1-4, 8, and 9 as did adult monocytes and T 
lymphocytes [104]. As studies of RLRs and ALRs are missing, we examined 
the expression levels of viral-sensing receptors (i.e., TLR3, TLR7, TLR8, 
TLR9, RIG-I, MDA-5, PKR, and IFI-16) in cord blood cells. 
The pilot analysis showed a lack of TLR3 expression in cord blood 
mononuclear cells (CBMC), whereas other nucleic acid-sensing receptors 
were expressed normally. This provided us with the basis for further TLR3 
analyses in newborns (Figure 8).  
 
 
Figure 8. Results from a pilot study of PRR expression in cord blood cells. 
 
The hypothesis underlying the work in Paper II was: 
♪  Newborns have impaired expression of PRRs 
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2.3 Paper III - TLR7 in CT-exposed PBMCs 
Taking into account the adjuvant characteristics of CT stated above, and 
addressing the mechanisms of CT activity, we asked if the adjuvant 
properties of CT could be associated with CT-induced up-regulation of 
PRRs. Adjuvants can be classified into two major functional groups: i) TLR-
dependent adjuvants, i.e., TLR agonists, which act directly on DCs through 
TLR activation and the induction of the expression of MHC II and co-
stimulatory molecules, cytokine secretion, and DC migration to the lymph 
nodes; and ii) TLR-independent adjuvants, e.g., alum, which act mainly to 
increase antigen uptake by APCs, although they also have 
immunostimulatory properties, which include leukocyte recruitment at the 
injection site and indirect DC activation through the induction of DAMP. To 
date, CT adjuvanticity has only been compared to that of TLR ligands, and 
there are no studies in the literature looking at whether CT induces/promotes 
TLR signalling. We surmised that CT might induce the expression of PRRs 
on innate immune cells. 
In a pilot experiment with two donors, we examined the expression levels of 
viral-sensing TLRs (i.e., TLR3, TLR7, TLR8, TLR9), RLGs (RIG-I, MDA-
5), PKR, and ALR (IFI-16) in peripheral blood mononuclear cells (PBMCs) 
after treatment with CT. A selective effect of CT on TLR7 mRNA expression 
was observed, so we investigated further the possible mechanisms behind this 
unexpected mode of modulation.  
The hypothesis underlying the work in Paper III was: 
♪  CT up-regulates PRR expression in innate immune cells 
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3 DISCUSSION 
3.1 Paper I 
In Paper I, we tested our hypothesis that CT activates DCs without inducing 
the immunoregulatory enzyme IDO. Initially, we showed that CT induces DC 
maturation, as the expression levels of MHC II molecule HLA-DR, the CD80 
and CD83 co-stimulatory molecules, and the CD83 maturation marker was 
up-regulated in CT-pulsed DCs. Although the CT-pulsing of DC led to a 
marked increase in IDO mRNA expression, measurements of the biological 
activity of IDO showed no measurable IDO-mediated degradation of 
tryptophan in the CT-pulsed DCs. Interestingly, although CT-pulsing alone 
did not promote the production of active IDO, CD40L stimulation of CT-
pulsed DCs resulted in increases in IDO mRNA expression and tryptophan-
degrading IDO activity. From these results it is concluded that:1) CT-pulsed 
DCs express IDO following the CD40-CD40L engagement that occurs when 
DCs and T cells interact; and 2) their ability to induce T-cell responses in 
DC-T cell co-cultures is retained even in the presence of IDO, since CT-
pulsed DCs were found to be highly efficient in stimulating both primary 
(allogeneic) and memory (autologous) CD4
+
 T-cell responses. Moreover, the 
addition of an inhibitor of IDO did not affect T-cell expansion, which 
indicates that IDO expression in CT-pulsed DCs is not causally related to 
their T-cell stimulatory ability. 
We compared CT-pulsed DCs with DCs that were matured in the presence of 
PGE2, TNF-α, and IL-1. These cytokines, together with IL-6, are considered 
the Gold standard for the ex vivo maturation of MDDCs used in clinical trials. 
PGE2, which is a lipid messenger that is released during inflammation, 
facilitates CCR7-mediated DC migration towards the lymph nodes in 
response to chemokines CCL19 and CCL21 and enhances their T-cell-
stimulatory capacity [105, 106]. PGE2 synergises with TNF-α in inducing DC 
maturation and greatly reduces the concentration of TNF-α required for IL-12 
production [107]. The use of PGE2 in clinical practice was called into 
question when it was discovered that PGE2 up-regulates IDO [108]. 
However, it was shown soon thereafter that the T-cell-priming ability of 
PGE2-matured, IDO-expressing DCs was not impaired, and that these cells 
stimulated even stronger T-cell proliferation than did mature MDDCs 
without active IDO [109]. It is clear that PGE2, in combination with other 
stimuli, can generate mature DCs that express IDO and that are strongly 
immunostimulatory. Similarly, LPS-matured MDDCs that express IDO are 
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more effective at stimulating T cells than immature DCs without active IDO 
[110]. This is not surprising, since mature DCs are known to be more 
efficient APCs than immature DCs, both in vitro and in DC-immunisation 
trials with healthy volunteers [111], and mature DCs are proven to be 
superior in inducing tumour-specific CTL responses in the treatment of 
patients with metastatic melanoma [112, 113]. This has led to the notion that 
IDO is not associated exclusively with immunosuppression but can 
participate in stimulating immunity. New light has been shed on the 
concordant results in the early years (mainly represented by the work of 
Munn and Mellor; [114]) on the immunoregulatory role of IDO. Over time, 
the portrait of a  DC-maturation process characterised by transition from an 
immature status that induces tolerance to a mature stage that directs immunity 
was replaced with a more “plastic” view, whereby mature DCs can present 
antigens in both immunogenic and tolerogenic manners (Figure 9).  
 
 
Figure 9. Overview of dendritic cell maturation and function in relation to IDO. 
 
Initially, we concurred with traditional opinion, and we surmised that 
immunostimulatory agents or adjuvants, such as CT, would not promote the 
expression of a tolerogenic factor, such as IDO. Although this was certainly 
true for CT activity alone, as we showed that CT is not a crucial stimulus for 
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IDO, we were surprised to find that CT-pulsing primed for CD40L-induced 
IDO expression. In the in vivo context, this suggests that CT-pulsed DCs 
express IDO after the CD40-CD40L interaction with T cells in the lymph 
nodes. The strong T-cell expansion in response to CT-pulsed DC that we 
observed (which in vivo also occurs in the lymph nodes/organs) implies that 
the potent immunostimulatory capacity and IDO expression coincide in CT-
matured DC. The same was valid for the mature DCs that we used as a 
positive control for IDO and strong T-cell-activating function. Nevertheless, 
the inhibition of IDO activity by the inhibitor 1-methyltryptophan (1-MT) in 
the assay did not influence T-cell proliferation, which indicates that, under 
our experimental conditions, T-cell activation was not under the control of 
IDO. Intriguingly, the IL-12p40 production that we detected upon CD40L 
stimulation in immature DCs, mature DCs, and even in CT-pulsed DCs (CT 
is not primarily a stimulator of IL-12) was blocked by 1-MT, which clearly 
indicates IDO-dependent IL-12p40 production in MDDCs. While we did not 
detect IL-12p70, as we did not provide a second signal (e.g., IFN-γ, LPS) 
required for its production, IL-12p40 itself has T-cell-stimulatory activity and 
potential to promote immune responses. Overall, our results support a 
positive effect of IDO on DC-effector functions, and are in accordance with 
existing knowledge regarding the contributions of IDO to DC maturation and 
the enhanced T-cell-stimulatory capacity of DCs. Several studies have 
identified critical roles for IDO in: a) eliciting the chemotactic and migratory 
activities of DCs [62]; b) increasing the expression of co-stimulatory 
molecules CD40, CD80, and CD86 [115]; c) stimulating the proliferation of 
naive T-cells [116].  
However, I must elaborate on some issues that prevent the drawing of 
straightforward conclusions. First, the levels of active IDO that we detected 
may have been too low to influence T-cell proliferation in response to CT-
pulsed DCs and cytokine-matured DCs. There are surprisingly contradictory 
data in the literature regarding the tryptophan/tryptophan metabolite 
concentrations required for any effect. Studies using human cells have shown 
that for T-cell proliferation to be inhibited, the tryptophan concentration must 
be 0.5–1.0 μM [52]. Of note, one group did not achieve inhibition of T-cell 
proliferation even when using medium without tryptophan [54]. As for 
tryptophan metabolites, concentrations of L-kynurenine and 3-
hydroxyanthranilic acid in the range of 5–50 μM were shown to be non-toxic 
for purified CD8
+
 T cells, while for apoptosis induction, a very high 
concentration of metabolites (500 μM) was needed over a longer period (5 
days of culture) [110]. The concentration of tryptophan metabolites required 
to inhibit T-cell proliferation is reported in some studies to be as high as 100 
μM [54, 55], although in other studies it is reported as being <10 μM [114, 
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117]. Therefore there is uncertainty as to the degree of IDO activity that is 
needed to disrupt T-cell function, regardless of whether this is mediated by 
tryptophan starvation or toxic metabolites. Although the decrease in 
tryptophan levels and increase in kynurenine concentrations observed in our 
experiments were comparable to those reported in previous studies, it seems 
likely that the MDDCs in our culture conditions did not generate sufficient 
levels of IDO activity to interfere with T-cell activation. Conversely, the T-
cell proliferation measured in our assay was very high, perhaps due in part to 
the high concentration of the T-cell-stimulatory cytokine IL-23, which was 
abundantly secreted by all the MDDC groups (immature, CT-pulsed, and 
cytokine-matured DCs).  
Second, if we regard IDO function from as a regulatory mechanism through 
which DCs dampen an immune response once the desired outcome has been 
achieved, then IDO is expected to be produced at a relatively late time-point 
during the immune reaction. We could not know whether IDO was produced 
during the T-cell proliferation assay, as it was not possible to analyse the co-
culture supernatants because of the conditioning medium that we used. In 
these experiments, Iscove´s medium was used, which prevents measurements 
of IDO activity by high performance liquid chromatography due to 
background interference with kynurenine /tryptophan detection. This leaves 
open the question as to whether the functional IDO was produced at later 
time-points during the assay. Another point should also be considered here. 
The tryptophan/kynurenine ratio is considered to be a reliable measure of 
IDO activity. However, other products formed along the kynurenine pathway, 
especially 3-OH-kynurenine and 3-OH-anthranilic acid, are also 
immunosuppressive. Thus, in the absence of any measurements of other 
tryptophan metabolites we cannot make definitive conclusions as to the 
contributions of IDO to DC maturation and T-cell-activating capacity.  
Third, the time for retrieval of the IDO-inducing signal is probably crucial for 
the cells. In the case of DCs, it is conceivable that the same factor(s) that 
signal for IDO have different outcomes depending on the time-point during 
DC maturation when they are present. In this respect, our experimental set-up 
has one major drawback. In our experiments, we supplied soluble CD40L to 
the MDDCs concomitantly with a 24-h period of stimulation with CT or a 
cocktail of cytokines, i.e., during DC maturation, and we then measured IDO 
activity. In contrast, in the DC-T cell experiments, the starting co-cultures 
contained DCs that had already matured for 24 h, and these cultures 
subsequently received the T cell-derived CD40L. Therefore, we based our 
inference regarding the T-cell-stimulatory capacity of IDO-expressing 
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MDDCs on IDO measurements that time-wisely do not correspond with each 
other. This is an issue that should be reconsidered.  
Fourth, even if a sufficient level of IDO activity was accomplished in our 
DC-T cell co-cultures, it remains a possibility that a negative impact of IDO 
on T-cell proliferation was overcome by other mechanisms. For instance, the 
tryptophan levels in the culture medium are adequate to neutralise the IDO-
mediated tryptophan starvation. Moreover, elevated levels of tryptophanyl-
tRNA-synthetase, the enzyme responsible for linking tryptophan with its 
cognate tRNA, were found in proliferating T cells that were stimulated with 
IDO-producing MDDCs [108]. This process “rescues” tryptophan from being 
degraded by IDO and is thought to represent an additional mechanism to 
counteract the negative effect of IDO on proliferating T cells. 
Investigations of IDO face several challenges. For example, 1-MT is used as 
a standard inhibitor of the enzymatic activity of IDO and to study 
immunoregulation mediated by IDO [58, 117]. However, two isoforms of 1-
MT exist, the L- and D-stereoisomers, and it is still not certain which isoform 
is the more effective at inhibiting IDO. 1-D-MT has been used extensively 
due to its strong ability to reverse IDO-mediated suppression of anti-tumour 
immunity in vivo, whereas in biochemical assays, 1-L-MT is more efficient at 
inhibiting IDO. We used both isoforms but did not observe any major 
differences in terms of effectiveness. Similarly, several other groups saw no 
improvement in T-cell proliferation when using 1-MT [118, 119]. Even 
though they generated mature MDDCs with the characteristic CD123
+
CCR6
+
 
phenotype, which according to Munn represent a human DC subset with 
constitutive expression of IDO and T-cell-inhibition capacity [117], these 
mature DCs did not express IDO. When stimulated to degrade tryptophan, 
these IDO-competent MDDCs did not inhibit T-cell proliferation [118, 119]. 
Of note, 1-MT seems to have an additional IDO-independent function, as 
evidenced by 1-MT enhancement of T-cell proliferation induced by cells 
defective in the production of IDO [120]. 
Given the above findings, a reasonable dilemma is the reliability of the in 
vitro system, as well is its correlation with the in vivo situation. DCs are 
known to be sensitive to the conditions under which they are cultured, and 
the same is true with regard to their production of IDO. Human studies of 
IDO are mainly performed with MDDCs, although it is known that certain 
factors in the methods used to obtain MDDCs, i.e., the nature of the culture 
medium or maturation cocktail, contribute to the functional expression of 
IDO [116]. Thus, in vitro studies may represent an artificial system in which 
IDO competence (expression and activity) is predominantly determined by 
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culturing factors rather than reflecting the intrinsic features of the studied 
cells. Nonetheless, the in vivo immunosuppressive role of IDO has been 
proven in mice [59, 61], and IDO expression has been detected in many 
human tumour biopsies [121, 122], implying that IDO functions in the same 
manner in humans. Furthermore, skin biopsies from patients with metastatic 
melanoma have shown FoxP3
+
 regulatory T cells infiltrating the site of 
vaccination with IDO-positive mature DCs, which suggests IDO-promoted 
recruitment of Tregs [123]. Taken together, these studies support the notion 
that IDO is not just an in vitro artefact, but rather that it behaves as in the 
organism. In mice, the IDO-producing cell population seems to be restricted 
to a specific DC subset in the spleen [124] or to a small fraction of pDCs, 
which drive IDO-mediated suppression in the tumour-draining lymph node 
[61]. It is not yet clear whether a distinct DC subset or certain fractions of 
many subsets of DCs with peculiar characteristics function as IDO-relevant 
DCs in vivo.  
Over the years, as different studies have confirmed or failed to confirm the 
initial results indicating the T-cell-suppressive role of IDO generated by 
IDO-expressing DCs, a new picture of the function of IDO-expressing human 
DCs emerged (Figure 10): i) without an appropriate signal received, the DCs 
do not express IDO; ii) DCs express IDO but the protein is not active and 
consequently, it has no influence on the T-cell responses; iii) DCs express 
IDO that actively degrades tryptophan but that does not have negative effects 
on T cells or T-cell activation; this is an area in which our results make a 
valuable contribution; and iv) DCs express functional IDO, which drives T-
cell suppression.  
 
Figure 10. Differential IDO expression profiles and the consequent functions of 
human DCs (adapted from Terness, Trends Immunol, 2006; 27(2):68) 
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In summary, we show that CT-induced maturation and the induction of 
competent IDO in DCs are events that are not separated in time. Thus, our 
original hypothesis was incorrect. Investigations of IDO are problematic in 
that the functionality of the enzyme is very susceptible to different 
environmental signals, the type of maturation stimulus, and the state of DC 
maturation We have yet to comprehend how the immune system harmonises 
the multiple biological roles of IDO, and under which circumstances identical 
signals determine whether the same IDO mechanism will carry out 
antimicrobial defence or immunosuppression. The roles of IDO under other 
normal physiological conditions, such as the maintenance of homeostatic 
tolerance or pregnancy, or under pathological conditions, such as the evasion 
of tumour immune surveillance, also await our clarification.   
 
 
3.2 Paper II 
In Paper II, we analysed the levels of basal expression and induced 
expression of transcripts for the viral nucleic acid-sensing receptors TLR3, 
TLR7, TLR8, TLR9, RIG-I, MDA-5, PKR, and IFI-16 in umbilical cord and 
adult blood cells. As presented in the Introduction section, in a pilot 
experiment we noticed striking impairment of TLR3 mRNA expression in 
CBMCs, as compared with PBMCs. To define the mononuclear cell type 
responsible for this deficiency of TLR3 mRNA, we first showed that adult 
NK cells of the CD56
dim
 subset contain the highest levels of TLR3 mRNA, 
and thereafter we focused our analyses on NK cells from cord and adult 
blood samples. The analyses of the same receptors on NK cells showed a 
similar selective impairment: the neonatal NK cells had an impaired TLR3 
mRNA expression and the TLR3 protein was absent.  
While unravelling the functional repercussions of TLR3 being absent, we 
found that neonatal NK cells were not able to respond to the TLR3 agonist 
poly(I:C) in terms of IFN-γ production, as compared with the abundant 
production of this cytokine by adult NK cells. Albeit to a lesser extent, the 
cytotoxic functions of neonatal NK cells induced upon TLR3 engagement 
were also affected; these cells were less competent at killing tumour cells 
after poly(I:C) stimulation, as compared with adult NK cells treated with 
poly(I:C). This phenomenon could not be attributed to an intrinsic defect of 
neonatal NK cells that resulted in inadequate cytotoxicity, since these cells 
attained adult levels of cytotoxicity upon activation with the NK cell-
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stimulatory cytokine IL-12. Neonatal NK cells were weakly cytotoxic 
towards HSV-2, possibly due to the impaired up-regulation of TLR3 mRNA 
triggered by HSV-2.   
Although it has been reported previously that neonatal NK cells are impaired 
in the secretion of IFN-γ [125], our results for the first time propose that the 
lack of TLR3 mRNA and protein expression in the NK cells from newborns 
is responsible for the aberrant TLR3-triggered IFN-γ production and 
cytotoxicity. A previous finding that a higher content of TLR3 mRNA in 
human NK cell clones correlated with higher levels of IFN-γ and cytotoxicity 
in response to TLR3 stimulation [126] suggested that TLR3 expression in 
NK cells is a prerequisite for a competent TLR3-mediated response. 
Compelling evidence comes from studies of children with HSV-1 
encephalitis who are deficient in TLR3 and consequently cannot exert a 
TLR3-mediated response [98], underlining a key role for TLR3 in the 
defence against HSV-1. TLR3 signalling has also been proposed to be 
involved in the immune response against HSV-2 [127-129]. We found that 
neonatal NK cells could not lyse HSV-1-infected cells and had impaired 
cytotoxicity towards HSV-2, in agreement with previous findings [77]. 
Viewed together, these results prompt us to speculate that the lack of TLR3 
underlies the hypersensitivity of newborns to HSV.    
Regarding how TLR3 expression is regulated, the detection of similar levels 
of TLR3 mRNA in the NK cells of men and women, as well as in pregnant 
women indicates that the systemic regulation of TLR3 expression is not 
influenced by either sex hormones or pregnancy. Instead, the marked 
difference in TLR3 mRNA levels noted between the NK cells from pregnant 
women and the NK cells from cord blood suggest that TLR3 expression is 
regulated in the uterus during pregnancy. Decidual NK cells that we obtained 
from the placenta at full-term delivery contained low levels of TLR3 mRNA 
expression as that of cord NK cells. This is not completely surprising given 
their CD56
bright
 phenotypes, since we revealed that the adult blood CD56
bright
 
NK cell subset expresses substantially less TLR3 mRNA than CD56
dim
 NK 
cells. To appreciate the significance of these findings, one needs to take into 
account the developmental relationship between the two subsets of blood NK 
cells. Although it is a matter of debate, the following lines of evidence 
support the idea that CD56
bright
 NK cells are the immature precursors of the 
more  highly differentiated CD56
dim
 NK cells: i) CD56
bright
 NK cells can be 
differentiated in vitro into CD56
dim
 cells [130], while the conversion in the 
opposite directions has not been seen; ii) after allogeneic or autologous bone 
marrow transplantation, NK cells are the main lymphocytes that populate the 
peripheral blood, and CD56
bright
 NK cells are the first to appear [131, 132]; 
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iii) the percentage of CD56
bright
  NK cells is higher in young adults and 
declines with age, while CD56
dim
 NK cells have the opposite pattern [133]; 
and iv) the shorter telomeres of CD56
dim
 NK cells denote a more mature stage 
[134]. Thus, if CD56
dim
 NK cells represent a more mature, TLR3-expressing 
subset, then the lower level of TLR3 expression on CD56
bright
 NK cells is 
associated with immaturity. The immaturity of cord NK cells is characterised 
by a higher inhibitory/activating receptor ratio and low or null expression of 
the terminal differentiation marker CD57, which is associated with higher 
cytotoxicity and lower cytokine production [71, 135, 136]. However, the 
percentage of CD56
bright
 NK cells is not higher in neonatal blood. It is 
conceivable that during pregnancy, a uterine environment rich in cytokines 
and hormones creates conditions that prevent the differentiation from 
CD56
bright 
to CD56
dim
. Disruption of the prevailing CD56
bright
 phenotype of 
the uterine NK cells has been linked to decreased fertility in women suffering 
from infertility of unknown cause; a higher percentage of CD56
dim
CD16
+
 NK 
cells was found in the follicular fluid, which may not be beneficial for oocyte 
maturation [137]. 
Decidual NK cells are formed during pregnancy in the decidua layer that 
lines the placenta, most probably through the recruitment and further tissue-
specific differentiation of the blood CD56
bright
 NK cells [138]. Apart from a 
role in immunity, decidual NK cells control trophoblast growth, 
differentiation, and invasion during the implantation process. Although 
decidual NK cells contain abundant cytotoxic granules with high 
concentrations of perforin and granzyme (despite the CD16
-
 phenotype) 
[139], they exhibit reduced cytotoxicity due to the immature formation of 
activating synapses [140]. Despite that their profile of activating receptors is 
complete and similar to that of other NK cells, some of the receptors on 
decidual NKs can transmit inhibitory signals due to the lack of an activating 
accessory protein [141]. Decidual NK cells do not kill trophoblast cells [142], 
although they lack the MHC I molecules HLA-A, HLA-B, and also HLA-C, 
which represents a deviation from the standard MHC-based NK-cell 
recognition concept. Instead, expression of the less polymorphic HLA-E and 
HLA-G as inhibitory receptor ligands is seen as a mechanism for immune 
unresponsiveness to trophoblasts (acting presumably by immobilising the 
decidual NK cells in the decidua and preventing their entry into the placenta) 
[143, 144]. Therefore, the normally poorly cytotoxic decidual NK cells 
evidently contribute to maintaining maternal immune tolerance towards the 
foetus, and increased cytotoxicity has been associated with harmful 
pregnancy outcomes, such as miscarriage [145, 146]. A recent study has 
revealed that the latter may be related to increased TLR3 expression in 
decidual NK cells, as women with unexplained recurrent spontaneous 
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miscarriage (range, 2–8 times) in the first trimester of gestation were found to 
have significantly higher levels of TLR3 mRNA and protein, as compared 
with women who electively terminated a normal pregnancy in the same 
gestation period [147]. Decidual NK cells from these patients showed 
significantly higher cytotoxicity against K562 tumour cells, implying a 
detrimental role of TLR3 in decidual NK cell activation and immune 
reactions to the foetus that might have caused miscarriage.  
This finding ties in with our results and proposal that weak expression of 
TLR3 in the pregnant uterus and the developing foetus, i.e., on maternal 
decidual NK cells and cord blood NK cells, respectively, represents a 
mechanism for tolerance at the maternal-foetal interface. The activation of 
TLR3, which elicits a strong Th1-type immune response, would be 
unfavourable in the context of inflammatory and allogeneic reactions, and 
might compromise the integrity of the foetus. Although we noted with 
interest the reduced TLR3 expression detected on neonatal CD8
+
 T cells, 
unfortunately we did not analyse the decidual CD8
+
 T cells. The decidua is 
not rich in lymphocytes, and those maternal CD8
+
 T lymphocytes located 
around the trophoblast are maintained in a tolerant status by HLA-G and 
inhibitory receptor interactions, which result in T-cell anergy [144]. It 
remains to be explored whether reduced TLR3 expression on cytotoxic cells, 
i.e., NK cells and T cells, prevents their over-activation and contributes to 
maternal-foetal tolerance.  
A possible mechanism for local regulation of TLR3 involves hormones. The 
TLR3 mRNA and protein are expressed in the uterine endometrial NK cells 
of non-pregnant women [148], as well as in the epithelial cells of the non-
pregnant endometrium. In these epithelial cells, the expression of TLR3 is 
subject to the cyclic, hormone-mediated regulation. Furthermore, hormone 
treatment of an endometrial cell line with estradiol abrogated the cytokine 
production induced by poly(I:C) [149].  
Besides its role in viral recognition, TLR3 has emerged as a receptor for 
DAMPs, recognizing self-RNA released from damaged tissues or during 
injuries associated with exposure to solar irradiation. TLR3 also drives an 
inflammatory response during tissue necrosis. The human placenta contains 
areas of intense necrosis, particularly in the decidua during trophoblast 
invasion in the course of implantation. Since decidual NK cells play roles in 
trophoblast invasion and angiogenesis, it can be speculated that the 
suppressed TLR3 expression in decidual NK cells prevents the onset of 
inappropriate TLR3-triggered inflammatory events. Indeed, CD56
+
 NK cells 
have been identified around the zone of decidual necrosis, and it has been 
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proposed that this “physiological necrosis” serves as a mechanism to divert 
the different maternal decidual inflammatory cells away from the arterioles 
where the trophoblast invasion and angiogenesis processes take place [150]. 
It is certain that foetuses, in a normally sterile uterus, constantly face the 
threat of intrauterine infections. The challenge is to achieve a balance 
between protection and pathological inflammation. TLRs, as the fundamental 
mediators of immune responses, are presumed to evoke adequate 
inflammatory reactions to clear the pathogen while avoiding foetal tissue 
damage. An association between viral infections of the genital tract and 
preterm labour has been reported [151-153], and intrauterine infections 
account for a high percentage of pre-term deliveries [154]. Pro-inflammatory 
cytokines (IL-1β, IL-6, TNF-α, IFN-γ) are suggested to have a causal role in 
early pregnancy abortion [155], and have been found at high concentrations 
in the amniotic fluids of women with intra-amniotic bacterial infection and 
pre-term labour [156, 157]. This supports the notion that up-regulation of 
TLR expression and TLR-triggered inflammation in the pregnant uterus 
signal for undesirable premature labour and pre-term delivery. In contrast, the 
inhibition of such TLR signalling systems would negatively affect the 
immune responses to viral infections. Our results confirm our hypothesis and 
show that the NK cells from cord blood do not express TLR3 and cannot 
harness the TLR3-triggered responses, as evidenced by impairments in IFN-γ 
production and cytotoxicity. These attributes of neonatal NK cells 
corroborate the overall picture of deficient cellular and Th1- type responses 
in newborns, and may predispose the baby to aberrant defence against HSV. 
 
 
3.3 Paper III 
In Paper III, we aimed to ascertain if CT could modulate PRR expression in 
adult PBMCs. Many adjuvants originate from microbial products and activate 
immune responses through engagement of PRRs. TLR ligands themselves are 
potent adjuvants for enhancing the APC functions of DCs, and CpG ODN 
stimulates the expression of its receptor, TLR9 [158]. However, some strong 
adjuvants are TLR-independent, e.g., aluminium-based adjuvants [159]. As 
already presented in the Aims section of the thesis, in a pilot study that 
analysed the effects of CT on the expression in PBMCs of transcripts for 
viral nuclear acid-sensing receptors TLR3, TLR7, TLR8, TLR9, RIG-I, 
MDA-5, PKR, and IFI-16, we uncovered a selective impact of CT on TLR7 
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expression. Overnight incubation of the PBMCs with CT resulted in the 
down-regulation of TLR7 expression, an effect that was seen already after 4 h 
and that increased further over time. When we examined the influence of CT 
on the cell types that dominantly express TLR7, i.e., pDCs and B cells, the 
same CT-induced decrease in TLR7 mRNA transcripts was observed.  
CT binds with high affinity to its specific receptor, the monosialoganglioside 
GM1, which is expressed on the cell membrane of all nucleated cells. GM1 
may be evenly expressed on the cell surface or may be grouped in specialised 
membrane invaginations (caveolae) that are rich in cholesterol, caveolin, and 
glycolipids. The binding of CTB to GM1 is used as the Gold standard to 
visualise these lipid rafts on different cells and to detect caveolae-mediated 
endocytosis [160, 161]. We aimed to examine the binding patterns of CT to 
different PBMC subpopulations, and to determine whether CT-mediated 
inhibition of TLR7 is preferentially exerted on TLR7 expressing cells owing 
to the higher level of binding of CT to these cells. Although all nucleated 
cells express GM1, the flow cytometry analysis revealed that neither the 
pDCs nor the B cells bound CTB on their surfaces. This was somewhat 
surprising as CTB binding to GM1 and the subsequent GM1 clustering and 
association with lipid rafts are crucial for CT trafficking into the cells, and 
thus represent a prerequisite for the activity of the toxin. Recently, it was 
shown that CT binding to DCs through GM1 is required for CT adjuvant 
activity [162]. However, another recent study has suggested that massive 
CTB binding to multiple GM1 receptors is not a strict precondition for CT-
mediated toxicity. CT holotoxin that contained chimeric B pentamers with 
only one single native GM1-binding site was able to attach to one GM1 
molecule, but this was enough for the CT-intoxication process [163]. This 
means that the level of CTB binding required for CT-mediated inhibition of 
TLR7 may have been below the detection limit of our flow cytometry 
analysis. The protein-receptor interactions are studied using more sensitive 
assays, e.g., a “flow cytometry protein-protein interaction assay”.   
Upon CTB binding to GM1, the CT-GM1 complex is internalised and 
transported into the endoplasmic reticulum via a retrograde trafficking 
pathway [164]. The CTA interacts non-covalently with the B subunit and is 
cleaved into the A1 and A2 chains. The carboxyl-terminus of the A2-chain 
stabilises the interactions with CTB and contains a sequence motif that is 
important for A1-chain trafficking (CT-A1). CT-A1 dissociates from the 
holotoxin and enters the cytosol. Here, it evades degradation by the 
proteasome due to its paucity of lysines residues, which are the sites of 
ubiquitination for misfolded host proteins. By virtue of its ADP-
ribosyltransferase activity, CT-A1 ADP-ribosylates the α-subunit of the 
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stimulatory G protein, resulting in constitutive activation of adenylate 
cyclase. The consequent increase in cAMP concentration leads to 
hyperactivation of protein kinase A (PKA).  
CT exerts most of its actions through the increasing the concentration of 
cAMP, and it has been shown that increasing cAMP levels by CT or other 
cAMP inducers is crucial in promoting the maturation of DCs [86, 165] and 
accounts in part for the adjuvant activity of CT [166]. Forskolin, which has 
the same cAMP-inducing property, is often used to determine the 
involvement in cellular processes of cAMP-mediated activities. Although we 
could show that CTA was required for the down-regulation of TLR7 mRNA 
(as this could not be achieved by CTB alone), the outcome was not a 
consequence of the CTA-induced increase in cAMP concentration or PKA 
involvement. Neither forskolin nor a cAMP analogue inhibited TLR7 mRNA 
expression. In addition, concomitant addition of PKA inhibitors together with 
CT did not influence the down-regulation of TLR7 mRNA expression. An 
increase in the level of cAMP does not explain all the observed effects of CT-
induced maturation of DCs [86, 167], and other pathways must be involved. 
For example, cAMP-independent regulation by CT is involved in the 
activation of T cells and B cells [168] and cytokine secretion by PBMCs 
[169]. It has also been proposed that the presence of CTA itself could account 
for the specific properties of CT, since in experiments using CT mutants with 
non-toxin CTA, adjuvant activity in vivo was preserved [170].   
PKC is a family of kinases that regulate the function of different proteins by 
phosphorylation of their serine and threonine residues. CT controls cytokine 
production by PBMCs through PKC [169]. There is evidence that PKC 
signalling interacts with TLR signalling, and this association is linked to 
TLR4-mediated cytokine secretion in macrophages [171]. In our 
experiments, the use of a PKC activator induced the same down-modulation 
of TLR7 mRNA as was seen with CT, which implies that CT acts through 
PKC. However, when we used PKC inhibitors, the disruption of the PKC 
pathway did not prevent CT-mediated TLR7 inhibition. These seemingly 
contradictory results suggest that CT regulates TLR7 transcription through 
not only the PKC signalling pathway, but also additional pathways.   
CT can act through the induction of soluble factors, such as PGE2 and nitric 
oxide (NO). These factors participate in the maturation of DCs induced by 
CT but also of bystander toxin-free DCs [165]. NO and superoxide anions 
directly stimulate DC maturation both phenotypically and functionally [172], 
and can act synergistically with other stimuli, such as LPS and TNF-α [173]. 
Among the many effects of NO, the best known is the activation of guanylate 
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cyclise, which converts GTP to cyclic GMP (cGMP), followed by the 
activation of cGMP-dependent protein kinase [174], a mechanism that we 
have not yet included in our analysis.    
Many of the effects of CT are accomplished through the induction of 
cytokine secretion. CT has been reported to induce in PBMCs the production 
of the immunostimulatory cytokines IL-1β and IL-6 [169], and these 
cytokines are, together with IL-8, secreted by epithelial cells of the intestine 
where they promote the in vivo immune response to CT. We detected 
abundant production of both IL-6 and IL-8 in CT-stimulated PBMCs and 
pDCs. In general, Th1 cytokine levels are proposed to correlate with 
enhanced TLR expression. In patients with intestinal inflammation, the 
mucosal Th1 cytokines correlate with enhanced intestinal TLR expression 
and signalling (i.e., TLR2, TLR3, and TLR4) [175, 176]. In contrast, Th2 
cytokines are known to down-regulate TLR signalling (TLR3 and TLR4) 
[177]. We attempted to ascertain whether the production of IL-6 and IL-8 that 
we observed is involved in the regulatory effect of CT on TLR7 expression. 
In a pilot experiment, we observed IL-6- and IL-8-induced down-regulation 
of TLR7 mRNA, mirroring the effect of CT. However, additional 
experiments are needed to confirm this potential regulatory mechanism.    
These results were rather surprising to us since we surmised that CT, which 
exerts an immunostimulatory adjuvant role on APC, would have the opposite 
effect. We have not fully managed to understand the implication of this 
unexpected finding, or the underlying mechanism(s). The CT-induced TLR7 
downregulation was not due to the toxic effects of CT, since CT seemed to 
prevent apoptosis in PBMC. CT can inhibit the cell-growth or induce 
apoptosis in some normal or tumour cells, mediated by either cAMP-
dependent [178] or independent mechanisms [179, 180]. Although in our 
experiments the observed inhibition of TLR7 mRNA expression required the 
CTA subunit, the consequent increase in cAMP concentration did not exert 
toxic effects on PBMC. In addition, other adjuvants or mitogens can enhance 
TLR7 expression (or have no effect), as we showed for the TLR9 ligand CpG 
ODN and the pokeweed mitogen. We also confirmed that S.aureus gives rise 
to a strong TLR7 upregulation, as shown previously [181]. These stimuli, 
similar to CT, also induce IL-6 and IL-8 production, which according to our 
preliminary data contributes to TLR7 mRNA downregulation; however, in 
contrast to CT, they also promote INF-α and/or IFN-γ responses [182, 183]. 
IFN-α/β is the main cytokine that positively regulates the expression of many 
TLR, including TLR7, and IFN-γ is also associated with the increased TLR 
expression in a variety of cell types [184, 185]. It is thus possible that the 
combination of several cytokines creates a tight regulatory mechanism that 
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overcomes the negative effects of some cytokines (i.e. IL-6) and positively 
controls TLR7 expression. We speculate that in the case of CT, the lack of 
IFN (IFN-α/β and/or IFN-γ) might contribute to TLR7 downregulation. We 
have yet to perform these experiments.  
TLR7 has recently been ascribed an important role in the development of 
autoimmune diseases in humans and mice [186]. In autoimmune-prone mice, 
duplication of the tlr7 gene promotes the development of a systemic lupus 
erythematosus (SLE)-like disease [187], while deletion of the gene confers 
disease resistance [188]. In contrast, autoimmune-resistant mice with tlr7 
gene copy number amplification develop spontaneous inflammation and 
autoimmunity [189]. Patients with SLE have increased serum levels of IFN-
α, secreted presumably by pDCs, which correspond to their levels of disease 
activity [190]. PBMCs from patients with SLE express higher levels of TLR7 
[191], and in some patients, tlr7 gene duplications have been detected and 
correlate with disease susceptibility [192]. The molecular basis for SLE and 
other autoimmune diseases, such as rheumatoid arthritis, is believed to stem 
from immune complexes, which are composed of autoantigens and self-RNA 
or self-DNA, which are endogenous ligands for TLR7 and TLR9, 
respectively. Studies that show that these autoimmune complexes can 
activate TLR9 signalling on pDCs and induce IFN-α production have 
suggested that the same mechanism may lead to TLR7 activation and the 
triggering of disease development [193]. RNA-containing immune 
complexes from patients with SLE induce Th1 cytokine production, and the 
released apoptotic material, which is rich in self nucleic acids, stimulates 
IFN-α secretion, a response that is terminated by RNases, which implies the 
involvement of TLR7 [186]. Taken together, these findings emphasise the 
deleterious impacts of TLR7 activation on inflammatory and autoimmune 
conditions. It seems that CT, conceivably in the course of infection with V. 
cholera or when used as an adjuvant, does not induce TLR7 up-regulation 
and is thus less likely to promote unwanted autoimmunity. Moreover, we 
postulate that CT, an adjuvant not associated with inflammation, may in the 
absence of TLR7 ligand engagement and activation, lead to TLR7 down-
regulation and thereby exert one of its anti-inflammatory adjuvant activities. 
In summary, our hypothesis that CT induces TLR expression was wrong. On 
the contrary, CT reduces TLR7 expression by pDCs and B cells, in a process 
that is cAMP- and PKA-independent but that involves PKC, and perhaps also 
IL-6. The relevance of this phenomenon, and whether it occurs in vivo, 
remains to be unravelled. However, our data imply that the transcription of 
the gene that encodes TLR7 is negatively regulated in a fashion different 
from that of other nucleic acid-sensing receptors. 
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